Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J Clin Oncol. 2025 03 20; 43(9):1113-1122.
-
Lee J, Tang Y, Cure?o Hernandez KE, Kim S, Lee R, Cartwright Z, Pochan DJ, Herrera-Alonso M. Ultrastable and Redispersible Zwitterionic Bottlebrush Micelles for Drug Delivery. ACS Appl Mater Interfaces. 2024 10 16; 16(41):55118-55129.
-
Rahmani Khalili N, Badiei A, Pirkani Z, Mohammadi Ziarani G, Vojoudi H, Golmohamadi A, Varma RS. Double-shelled, rattle-architecture covalent organic framework: harnessing morphological manipulation for enhanced synergistic multi-drug chemo-photothermal cancer therapy. J Mater Chem B. 2024 Aug 14; 12(32):7915-7933.
-
Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
Huang H, Hwang J, Anilkumar S, Kiick KL. Controlled Release of Drugs from Extracellular Matrix-Derived Peptide-Based Nanovesicles through Tailored Noncovalent Interactions. Biomacromolecules. 2024 04 08; 25(4):2408-2422.
-
Sullivan MO, Chen W. Engineering E2 Bionanoparticles for Targeted Delivery of Chemotherapeutics to Breast Cancer Cells. Methods Mol Biol. 2024; 2720:177-189.
-
Braunstein Z, Waller A, Dotson E, McLaughlin E, Hanel W, Reneau J, Addison D, Porcu P, Brammer JE. Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas. Leuk Lymphoma. 2024 03; 65(3):301-311.
-
DuBois SG, Krailo MD, Glade-Bender J, Buxton A, Laack N, Randall RL, Chen HX, Seibel NL, Boron M, Terezakis S, Hill-Kayser C, Hayes A, Reid JM, Teot L, Rakheja D, Womer R, Arndt C, Lessnick SL, Crompton BD, Kolb EA, Daldrup-Link H, Eutsler E, Reed DR, Janeway KA, Gorlick RG. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 04 10; 41(11):2098-2107.
-
Hund HC, Frantz SK, Wu H, Adeniran OR, Wong TY, Borgmann AJ, Matsuoka L, Geevarghese S, Alexopoulos S, Shingina A, Meranze SG, Baker JC, Garbett S, Brown DB. Six-Year Evaluation of Same-Day Discharge following Conventional Transarterial Chemoembolization of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2023 03; 34(3):378-385.
-
Joyce DD, Wymer KM, Sharma V, Moriarty JP, Borah BJ, Geynisman DM, Plimack ER, Costello BA, Pagliaro LC, Boorjian SA. Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. Cancer. 2022 12 15; 128(24):4194-4202.